[14]
Singh, T.; Singh, R.; Verma, V.K.; Nakayama, K. A study of N, O and S heterocyclic compounds as extreme pressure lubricant additives. Tribol. Int., 1990, 23(1), 41-46.
[31]
Dua, R.; Dua, R.; Shrivastava, S.; Sonwane, S.K.; Srivastava, S.K. Pharmacological significance of synthetic heterocycles scaffold: A review. Adv. Biol. Res. (Faisalabad), 2011, 5(3), 120-144.
[64]
Ghosh, R.; Hansda, S. Targeted and non-targeted effects of radiation in mammalian cells: An overview. Arch. Biotech. Biomed., 2021, 5(1), 13-19.
[66]
Mo, K.; Park, J.H.; Kang, S.B.; Kim, Y.; Lee, Y.S.; Lee, J.W. Synthesis of pyrazine via chemoselective reduction of b-keto-a-oximino ester using baker’s yeast. J. Mol. Cat., B Enzym., 2016, 129, 29-34.
[70]
Majno, G.; Joris, I. Cells, tissues and disease; Oxford University Press, 2004.
[71]
Kumar, V.; Cotran, R.S.; Robbins, S.L.; Basic, R. Pathology; Saunders, 2003.
[74]
Sanagi, M.M.; Hung, W.P.; Yasir, S.M. Supercritical fluid extraction of pyrazines in roasted cocoa beans. Effect of pod storage period. J. Chromatogr. A, 1997, 785(1-2), 361-367.
[84]
Dolezal, M.; Zitko, J. Pyrazine derivatives: A patent review (June 2012–present). Expert Opin. Ther. Pat., 2015, 25(1), 33-47.
[93]
Hara, T.; Norimatsu, N.; Kurushima, H.; Kono, T. Method for producing dichloropyrazine derivative. EP2392566A1 2014, US024832,
[96]
Dhurwasulu, B.; Grether, U.; Nettekoven, M. Novel pyrazine derivatives as CB2 receptor agonists. MX2015006036A 2014, WO086807,
[97]
Woodward, R.M. Use of opioid receptor antagonist for gastrointestinal tract disorders. MX003310, 2012.
[98]
Bylock, L.A. Oxadiazoles as inhibitors of leukotriene production for combination therapy and their preparation. WO0195879, 2013.
[102]
Cotrel, C.; Jeanmart, C.; Messer, M.N. Pyrrolo(3,4-b)pyrazine derivatives. DE2300491, 1973.
[104]
Boyle, R.G.; Boyce, R.J. Pharmaceutically active pyrazine derivatives. WO072502, 2013.
[105]
Collins, I.; Lainchbury, M.; Matthews, T.P.; Reader, J.C. Preparation of 5-(pyridin-2-ylamino)pyrazine-2-carbonitrile compounds as CHK1 inhibitors. WO068755, 2013.
[106]
Wishart, N.; Bonafoux, D.F.; Frank, K.E. Preparation of imidazopyrrolopyrazine derivatives and analogs for use as protein kinase modulators. US0072470, 2013.
[107]
Ito, Y.; Kushida, I.; Mitasev, B. Fused aminodihydrothiazine derivative salts as BACE1 inhibitors and their preparation. WO015125, 2014.
[108]
Lewis, R.T.; Choquette, D.; Epstein, O. Aminodihydrothiazine and aminodioxodihydrothiazine compounds as beta-secretase antagonists and their preparation. WO059185, 2014.
[109]
Le Clerq, L.C.; Bartolome-Nebreda, J.M.; Conde-Ceide, S.; Van Gool, M.L.M. Inhibitors of phosphodiesterase 10 enzyme. WO009305, 2014.
[111]
Galley, G.; Norcross, R.; Pflieger, P. Preparation of pyrazine derivatives as inhibitors of TAARs. WO072257, 2014.
[112]
Charrier, J.D.; Storck, P.H.; Pinder, J.; Studley, J.R. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US0115312, 2013.
[113]
Charrier, J.D.; Kay, D. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US20130115314, 2013.
[114]
Charrier, J.D.; Durrant, S.J.; Knegtel, R. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US20130115310, 2013.